These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 10444196

  • 1. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 2. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ.
    Lancet; 2003 Jan 11; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract] [Full Text] [Related]

  • 3. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug 11; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 4. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 5. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 6. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
    Aydinok Y, Nisli G, Kavakli K, Coker C, Kantar M, Cetingül N.
    Acta Haematol; 1999 Jan 11; 102(1):17-21. PubMed ID: 10473883
    [Abstract] [Full Text] [Related]

  • 7. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R, Engelhardt R.
    Lancet; 2003 Jan 11; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract] [Full Text] [Related]

  • 8. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser MD, Koren G, Roifman CM, Olivieri NF.
    Br J Haematol; 1997 Sep 11; 98(3):597-600. PubMed ID: 9332313
    [Abstract] [Full Text] [Related]

  • 9. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment.
    Athanassiou-Metaxa M, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi-Tsakalidou F.
    Acta Haematol; 2003 Sep 11; 110(4):224-6. PubMed ID: 14663175
    [No Abstract] [Full Text] [Related]

  • 10. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
    Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A.
    Br J Haematol; 2003 Apr 11; 121(1):187-9. PubMed ID: 12670352
    [Abstract] [Full Text] [Related]

  • 11. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A.
    Br J Haematol; 2003 Jun 11; 121(6):938-48. PubMed ID: 12786807
    [Abstract] [Full Text] [Related]

  • 12. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.
    Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M.
    Haematologica; 2009 Dec 11; 94(12):1777-8. PubMed ID: 19815834
    [No Abstract] [Full Text] [Related]

  • 13. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G.
    Haematologica; 2006 Jun 11; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [Abstract] [Full Text] [Related]

  • 14. Iron chelators for thalassaemia.
    Hershko C, Konijn AM, Link G.
    Br J Haematol; 1998 Jun 11; 101(3):399-406. PubMed ID: 9633877
    [No Abstract] [Full Text] [Related]

  • 15. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 11; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 16. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, Usai B, Matta G, Galanello R.
    Eur J Heart Fail; 2007 Mar 11; 9(3):320-2. PubMed ID: 17029959
    [Abstract] [Full Text] [Related]

  • 17. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 19. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A.
    Blood; 2006 May 01; 107(9):3733-7. PubMed ID: 16373663
    [Abstract] [Full Text] [Related]

  • 20. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ.
    J Cardiovasc Magn Reson; 2012 Jan 25; 14(1):8. PubMed ID: 22277065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.